Chris Hurt

Cardiff University School of Medicine

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (24)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (11)

Pradeep Virdee

University of Oxford

UNITED KINGDOM

View details

Emma Hall

Institute of Cancer Research

UNITED KINGDOM

View details

Andrew Cook

University of Southampton

UNITED KINGDOM

View details

Maria Andreia Hawkins

University College London

UNITED KINGDOM

View details

Lisette Nixon

Senior Research Fellow; Deputy Head of Trial Management (Cancer)

Cardiff University

UNITED KINGDOM

View details

Richard Adams

Professor

Cardiff University

UNITED KINGDOM

View details

Samantha Hinsley

University of Glasgow

UNITED KINGDOM

View details

Emiliano Spezi

Professor of Healthcare Engineering and Director of Research

Cardiff University

UNITED KINGDOM

View details

Timothy Stanley Maughan

Professor of Clinical Oncology, CRUK/MRC Oxford Institute for Radiation Oncology

University of Oxford

UNITED KINGDOM

View details

Simon Bach

University of Birmingham

UNITED KINGDOM

View details

David Sebag-Montefiore

Professor of Clinical Oncology and Health Research

University of Leeds

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Chris Hurt

Research Interests

Explore related searches

Contact this professor

Articles (24)

Understanding the variation of modern endoscopic ultrasound use in patients with oesophageal cancer (VALUE): protocol for a multi-methods study

Radiotherapy Quality Assurance in the SCOPE2 Trial: What Lessons can be Learned for the Next UK Trial in Oesophageal Cancer?

Reflection on Transoral Robotic Surgery vs Transoral Laser Microsurgery in HPV-Positive Oropharyngeal Squamous Cell Carcinoma—Reply

Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial

Assessment of endpoint definitions in curative-intent trials for mucosal head and neck squamous cell carcinomas: Head and Neck Cancer International Group consensus recommendations

Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations

Aspiration Rates and Clinician-graded Dysphagia after Transoral Surgery (TOS): An Interim Analysis of Modified Barium Swallow (MBS) Studies (videofluoroscopy) from the PATHOS trial

121 Differential functional outcomes following transoral surgery for oropharyngeal carcinoma -laser versus robot

122 Objective evaluation of plan quality in the PATHOS clinical trial using automated treatment planning

49 Development of a Normal Tissue Complication Probability Model for Dysphagia in PATHOS trial patients

The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors

Transoral Laser or Robotic Surgery Outcomes for Oropharyngeal Carcinoma

Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial

BI06 Short sharp shock or slow burn: clinician perspectives on treatment of actinic keratoses with 5-fluorouracil 5% cream monotherapy vs. 5-fluorouracil/calcipotriol ointment combination therapy

ABC-12: Exploring the microbiome in patients (pts) with advanced biliary tract cancer (BTC) in a first-line study of durvalumab in combination with cisplatin/gemcitabine (cis/gem).

A Road Map for Designing Phase I Clinical Trials of Radiotherapy–Novel Agent Combinations

Implementing effective community-based surveillance in research studies of maternal, newborn and infant outcomes in low resource settings

Combined HPV 16 E2 and L1 methylation predict response to treatment with cidofovir and imiquimod in patients with vulval intraepithelial neoplasia

Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial

Stent insertion for incurable oesophageal carcinoma: what is the optimal treatment? – Authors' reply

Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma

Technique for inguino-femoral lymph node dissection in vulvar cancer: an international survey

Collaborators (11)

Pradeep Virdee

Emma Hall

Andrew Cook

Maria Andreia Hawkins

Lisette Nixon

Richard Adams

Samantha Hinsley

Emiliano Spezi

Timothy Stanley Maughan

Simon Bach

David Sebag-Montefiore

Make your next move.